Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

TRANSBIO

Financiado

Cerrado

Cellular BIOtechnology for prognosis and monitoring in renal TRANSplantation

Kidney transplantation is the treatment of choice for patients with end-stage kidney disease (ESKD). However, although surgical techniques and postoperative care have greatly advanced, renal transplantation is not empty of challen... ver más

30/06/2019

BIOHOPE SCIENTIFIC...

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

BIOHOPE SCIENTIFIC SOLUTIONS FOR HUMAN HEALTH Objeto. la sociedad tendrá por objeto las siguientes actividades: 1. investigación, desarrollo experimental e innovación en biotecnología. 2...

TRL 3-4 | 1M€

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-06-30

SMEInst-05-2016-2017: Supporting innovative SMEs in the h...

I+D

Cerrada hace 8 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

BIOHOPE SCIENTIFIC SOLUTIONS...

3.85M€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

TRANSBIO A BIOmarker based assay for prognosis and monitoring in rena... 71K€ Cerrado

TOLERANCE Targeting innate immunity to induce TOLERANCE in transplanta... 3M€ Cerrado

PRESERVE Preventing rejection and ensuring survival of grafts Cerrado

KiT-FIG Kidney Transplantation Functional ImmunoGenomics 197K€ Cerrado

SAF2015-64224-R ENDOTELIZACION INTER-ESPECIES COMO ESTRATEGIA PARA LA REALIZ... 121K€ Cerrado

BIO-DrIM Personalized minimization of immunosuppression after solid o... 8M€ Cerrado

Duración del proyecto: 33 meses Fecha Inicio: 2016-09-26
Fecha Fin: 2019-06-30

Líder del proyecto

BIOHOPE SCIENTIFIC SOLUTIONS FOR HUMAN HEALTH Objeto. la sociedad tendrá por objeto las siguientes actividades: 1. investigación, desarrollo experimental e innovación en biotecnología. 2...

TRL 3-4 | 1M€

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Kidney transplantation is the treatment of choice for patients with end-stage kidney disease (ESKD). However, although surgical techniques and postoperative care have greatly advanced, renal transplantation is not empty of challenges. The most important challenge is to achieve the long-term survival of the transplanted organ. Graft survival depends on the ability of the recipe of not rejecting the foreign organ. Rejection is a naturally occurring process triggered by a biological response of the immune system, which main function in the body is to defend it against infectious organisms and other invaders. As such, the immune system is prepared to reject a foreign organ, something that is nowadays prevented by prescribing immunosuppressive therapies to the patients for their whole life. However, the use of immunosuppressive therapies entails important problems. On one side, suppressing the immune system implies severe side effects like opportunistic infections, cancer and other severe malignancies. On the other side, even under immunosuppressive therapies, about 50% of transplanted kidneys are lost during the first 10 years and this is because of an immune response usually described as chronic rejection. Therefore, the major challenges in ESKD deal with avoiding the side effects associated with immunosuppressant drugs and avoiding chronic rejection. In the TRANSBIO project we aim at bringing to the healthcare market a technology for efficient clinical management of patients undergoing a kidney transplant based on a simple and non-invasive blood test. Considering that worldwide, the number of people receiving renal transplantation annually is estimated at about 80,000 people, growing by approximately 6% annually and representing a prevalence of about 700 patients per million population, or what is the same about 5 million people living with a transplanted kidney, the TRANSBIO business opportunity seems unquestionable.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores